FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3134765043> ?p ?o ?g. }

• W3134765043 endingPage "1056" @default.
• W3134765043 startingPage "1054" @default.
• W3134765043 abstract "To evaluate the long-term effect of subthreshold nanosecond laser (SNL) treatment on progression to late age-related macular degeneration (AMD).Observational extension study of a randomized, sham-controlled trial.Two hundred twelve participants with bilateral large drusen.The Laser Intervention in the Early Stages of AMD (LEAD) study was a 36-month trial where participants were randomized to receive SNL or sham treatment in 1 eye at 6-monthly intervals up to 30 months. After the completion of the LEAD study, the 2 largest recruiting sites offered remaining participants an opportunity to enroll in a 24-month observational extension study. This study thus examined all participants from these 2 sites who were enrolled in the LEAD study at baseline, including the additional observational data.Time to develop late AMD, defined on multimodal imaging, between those randomized the SNL or sham treatment.Overall, no significant difference was found in the rate of progression over a 60-month period in those randomized to the SNL compared with the sham group (adjusted hazard ratio [HR], 0.63; 95% confidence interval [CI], 0.36–1.09; P = 0.098), similar to the findings at 36 months in the LEAD Study. However, evidence of treatment effect modification continued to emerge based on the coexistence of reticular pseudodrusen (RPD; P = 0.007, adjusted interaction). Namely, progression was slowed significantly with SNL treatment for those without coexistent RPD (adjusted HR, 0.34; 95% CI, 0.16–0.71; P = 0.004), but it was not significantly different for those with RPD (adjusted HR, 1.81; 95% CI, 0.67–4.88; P = 0.239).A 24-month observational extension study to the LEAD Study confirmed that SNL treatment did not significantly reduce the overall rate of progression to late AMD in a cohort with intermediate AMD. However, the persistence of a potential beneficial treatment effect in those without coexistent RPD over a longer follow-up duration of an additional 24 months without additional treatment is encouraging. These findings provide further justification for future trials to examine the potential value of SNL treatment for slowing progression in intermediate AMD." @default.
• W3134765043 created "2021-03-15" @default.
• W3134765043 creator A5003577606 @default.
• W3134765043 creator A5003995989 @default.
• W3134765043 creator A5007745294 @default.
• W3134765043 creator A5033560866 @default.
• W3134765043 creator A5048241818 @default.
• W3134765043 creator A5060172197 @default.
• W3134765043 creator A5066434934 @default.
• W3134765043 date "2021-10-01" @default.
• W3134765043 modified "2023-09-26" @default.
• W3134765043 title "Attendance Rate in Patients with Diabetic Macular Edema Receiving Short Messages" @default.
• W3134765043 cites W2794935335 @default.
• W3134765043 cites W2803487511 @default.
• W3134765043 cites W2899990204 @default.
• W3134765043 doi "https://doi.org/10.1016/j.oret.2021.03.005" @default.
• W3134765043 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33691182" @default.
• W3134765043 hasPublicationYear "2021" @default.
• W3134765043 type Work @default.
• W3134765043 sameAs 3134765043 @default.
• W3134765043 citedByCount "1" @default.
• W3134765043 countsByYear W31347650432023 @default.
• W3134765043 crossrefType "journal-article" @default.
• W3134765043 hasAuthorship W3134765043A5003577606 @default.
• W3134765043 hasAuthorship W3134765043A5003995989 @default.
• W3134765043 hasAuthorship W3134765043A5007745294 @default.
• W3134765043 hasAuthorship W3134765043A5033560866 @default.
• W3134765043 hasAuthorship W3134765043A5048241818 @default.
• W3134765043 hasAuthorship W3134765043A5060172197 @default.
• W3134765043 hasAuthorship W3134765043A5066434934 @default.
• W3134765043 hasConcept C118487528 @default.
• W3134765043 hasConcept C126322002 @default.
• W3134765043 hasConcept C168563851 @default.
• W3134765043 hasConcept C207103383 @default.
• W3134765043 hasConcept C23131810 @default.
• W3134765043 hasConcept C2776403814 @default.
• W3134765043 hasConcept C44249647 @default.
• W3134765043 hasConcept C71924100 @default.
• W3134765043 hasConceptScore W3134765043C118487528 @default.
• W3134765043 hasConceptScore W3134765043C126322002 @default.
• W3134765043 hasConceptScore W3134765043C168563851 @default.
• W3134765043 hasConceptScore W3134765043C207103383 @default.
• W3134765043 hasConceptScore W3134765043C23131810 @default.
• W3134765043 hasConceptScore W3134765043C2776403814 @default.
• W3134765043 hasConceptScore W3134765043C44249647 @default.
• W3134765043 hasConceptScore W3134765043C71924100 @default.
• W3134765043 hasFunder F4320312649 @default.
• W3134765043 hasIssue "10" @default.
• W3134765043 hasLocation W31347650431 @default.
• W3134765043 hasLocation W31347650432 @default.
• W3134765043 hasOpenAccess W3134765043 @default.
• W3134765043 hasPrimaryLocation W31347650431 @default.
• W3134765043 hasRelatedWork W1977391174 @default.
• W3134765043 hasRelatedWork W2313076522 @default.
• W3134765043 hasRelatedWork W2508640481 @default.
• W3134765043 hasRelatedWork W2730859660 @default.
• W3134765043 hasRelatedWork W2772400303 @default.
• W3134765043 hasRelatedWork W3134475916 @default.
• W3134765043 hasRelatedWork W4287836494 @default.
• W3134765043 hasRelatedWork W4297541668 @default.
• W3134765043 hasRelatedWork W4318763410 @default.
• W3134765043 hasRelatedWork W4377192380 @default.
• W3134765043 hasVolume "5" @default.
• W3134765043 isParatext "false" @default.
• W3134765043 isRetracted "false" @default.
• W3134765043 magId "3134765043" @default.
• W3134765043 workType "article" @default.